GlassScriptPhysician profile
Bridget Margaret Dewey
NPI 1073516647
$578.71
in general payments reported to CMS, 2019-2025
21 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $55.75 · 2021: $106 · 2022: $124 · 2023: $14.36 · 2024: $137 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $140.16 | 2022-2025 | Gallant |
| Astrazeneca Pharmaceuticals LP | $63.07 | 2020-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $56.09 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $41.40 | 2020-2021 | |
| Abbvie INC. | $30.82 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.05 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $20.30 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $19.62 | 2024 | Eliquis |
| Eisai INC. | $17.85 | 2021 | |
| Medtronic, INC. | $16.78 | 2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $15.94 | 2025 | Belbuca |
| Merck Sharp & Dohme LLC | $15.52 | 2024 | Dificid |
| Gilead Sciences, INC. | $14.55 | 2024 | |
| Horizon Therapeutics Plc | $14.36 | 2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.46 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.44 | 2020 | |
| Incyte Corporation | $12.95 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $7.72 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Dewey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.